Sacrosidase is a naturally-occurring gastrointestinal enzyme derived from baker’s yeast (Saccharomyces cerevisiae) which breaks down the disaccharide sucrose to its monosaccharide components. Hydrolysis is necessary to allow absorption of these nutrients.

Pre-Authorization Criteria:
Sacrosidase is indicated as oral replacement therapy of the genetically determined sucrose deficiency, as seen in congenital sucrose-isomaltase deficiency (CSID).

VCHCP requires that Sacrosidase be prescribed by a physician specializing in the condition being treated.

Prescribing and Access Restrictions:
Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to http://www.sucraid.net/how-to-order-sucraid or call 1-866-740-2743.

Dosing: Adult:
Congenital sucrase-isomaltase deficiency (CSID): Oral: 17,000 units (2 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.

Dosing: Pediatric:
Congenital sucrase-isomaltase deficiency (CSID): Infants ≥5 months and Children ≤15 kg: Oral: 8500 units (1 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack. Children >15 kg and Adolescents: Refer to adult dosing.

Dosing: Geriatric:
Refer to adult dosing.

Dosing: Renal Impairment:
No dosage adjustment provided in manufacturer’s labeling.

Dosing: Hepatic Impairment:
No dosage adjustment provided in manufacturer’s labeling.
Dosage Forms: U.S.:  
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  
Solution, Oral:  
Sucraid: 8500 units/mL (118 mL) [contains papain]  
Generic Equivalent Available: U.S.-No  

Administration:  
Dilute dose in 2-4 oz of cold or room temperature water, milk, or formula; avoid fruit juices or warm or hot food/liquids (may lower potency).  

Adverse Reactions:  
Headache, insomnia, nervousness, dehydration, abdominal pain, constipation, diarrhea, nausea, vomiting.  
Other Serious Less Common Reactions: Hypersensitivity reactions, wheezing  

Contraindications:  
Hypersensitivity to yeast, yeast products, glycerin (glycerol) or papain  

References:  

Revision History:  
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD  
Date Approved by P&T Committee: 1/27/15  
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/26/16  
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/24/17  
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/23/18  
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/22/19
## DRUGS POLICIES

**VCHCP**

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>